D. E. Shaw & Co. Inc. Has $24.46 Million Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

D. E. Shaw & Co. Inc. raised its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 16.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,110,501 shares of the company's stock after purchasing an additional 155,086 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.54% of Cellebrite DI worth $24,464,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of CLBT. Barclays PLC increased its stake in Cellebrite DI by 29.1% in the third quarter. Barclays PLC now owns 263,657 shares of the company's stock valued at $4,439,000 after purchasing an additional 59,395 shares in the last quarter. Principal Financial Group Inc. acquired a new position in shares of Cellebrite DI in the third quarter valued at approximately $23,402,000. JPMorgan Chase & Co. boosted its holdings in shares of Cellebrite DI by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company's stock valued at $7,202,000 after buying an additional 75,092 shares during the period. Jackson Square Capital LLC acquired a new position in shares of Cellebrite DI in the fourth quarter valued at approximately $1,596,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Cellebrite DI by 2,244.2% in the fourth quarter. SG Americas Securities LLC now owns 209,529 shares of the company's stock valued at $4,616,000 after buying an additional 200,591 shares during the period. Institutional investors own 45.88% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday. Needham & Company LLC reduced their target price on shares of Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Lake Street Capital increased their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $22.43.

Cellebrite DI Stock Down 3.0%

Shares of CLBT traded down $0.54 during trading hours on Thursday, hitting $17.27. The company had a trading volume of 1,771,749 shares, compared to its average volume of 1,451,941. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30. The firm has a market cap of $4.14 billion, a price-to-earnings ratio of -12.42, a PEG ratio of 4.27 and a beta of 1.44. The business has a fifty day moving average of $19.01 and a 200-day moving average of $20.25.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, equities analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.